Developing first-in-kind preclinical models of primary testicular lymphoma

Ended Project Grant Awarded Last action

Award ID
HT94252410867
Recipient
Awarding agency
Obligated
$109,895

Award facts

Assistance listing
12.420 Military Medical Research and Development
Completion date
Place of performance
2323 Riverside Dr., Ottawa, ON K1H 1A1, Canada

Award details come from USAspending.gov.

About this award

Written by GovTribe AI ·

The U.S. Defense Health Agency awarded a $109,895 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Provincial Health Services Authority (operating as BC Cancer) in Canada. The grant is for the purpose of "DEVELOPING FIRST-IN-KIND PRECLINICAL MODELS OF PRIMARY TESTICULAR LYMPHOMA" over a 2-year period from September 1, 2024 to August 31, 2026. As a prominent Canadian healthcare organization specializing in cancer research, treatment, and prevention, BC Cancer will leverage its expertise in oncology to conduct this comprehensive research project aimed at developing innovative preclinical models for primary testicular lymphoma, a rare and understudied cancer type. The award contributes to the program's broader objectives of advancing military medical research and improving health outcomes for service members, veterans, and the general public.

Quick answers

Who received award HT94252410867?

HT94252410867 was awarded to Provincial Health Services Authority by Defense Health Agency (Department of Defense) on September 1, 2024.

How much is award HT94252410867 worth?

$109,895 has been obligated on HT94252410867.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login